Novo Nordisk is partnering with Anthropic to accelerate the development of new medicines using AI. The Danish drugmaker will use Anthropic’s Claude Science, a set of capabilities intended to support scientific work, to help advance drug discovery efforts.
The collaboration centers on applying Anthropic’s frontier models to address technical challenges in drug discovery. Quartz reports that the work includes both tackling drug discovery problems and using AI systems to support software development related to these efforts. NDTV similarly describes the partnership as a way to speed up the creation of new medicines, highlighting the use of Claude.
While both outlets agree on the core partnership and the intent to accelerate drug discovery, the coverage differs slightly in emphasis. Quartz provides more detail on the types of tasks, including AI-driven software development, whereas NDTV focuses more broadly on the use of Claude to accelerate medicine development.
The companies do not provide additional publicly shared specifics in the supplied excerpts, such as timelines, financial terms, or named drug candidates.
